A multicentre, retrospective study to evaluate the role of HLA -C*06 as a pharmacogenetic marker of response to ustekinumab.
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Ustekinumab (Primary)
- Indications Plaque psoriasis
- Focus Pharmacogenomic; Therapeutic Use
- 27 Feb 2017 New trial record
- 16 Feb 2017 Primary endpoint has been met (The proportion of patients achieving at least 50% reduction in the PASI score (PASI 50) at week 4.), according to results published in the British Journal of Dermatology.
- 16 Feb 2017 Results published in the British Journal of Dermatology